Semaglutide
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Mechanism of Action
Mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through hypothalamic signaling. The result is significant reduction in food intake and improved glycemic control.
Dosage Overview
Dose Range
250 mcg – 2.4 mg
Route
subcutaneous
Frequency
Weekly
Cycle Length
12–52 weeks
Reconstitution
Typical Dosage (Research)
Wegovy (weight loss): Start at 0.25mg weekly, titrate up to 2.4mg weekly over 16-20 weeks. Ozempic (diabetes): 0.25mg to 1mg weekly. Research protocols vary.
Subcutaneous injection once weekly, typically in abdomen, thigh, or upper arm. Rybelsus is taken orally on empty stomach. Dose titration is essential to minimize GI side effects.
Considerations for Men & Women
Women: Contraindicated during pregnancy; discontinue at least 2 months before planned conception due to long half-life. May affect menstrual cycle regularity. Weight loss can increase fertility in women with PCOS by restoring ovulation. May reduce the efficacy of oral contraceptives due to delayed gastric emptying — use backup contraception during initial dose titration.
Men: May improve testosterone levels secondary to weight loss, particularly in men with obesity-related hypogonadism. Some studies show improvements in erectile function and fertility markers as BMI normalizes. No specific dose adjustments needed compared to women.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 2,000 mcg/ml
Volume to inject: 0.13 ml
Syringe units (U-100): 12.5 units
Pre-filled with Semaglutide defaults. Adjust values as needed.
Side Effects & Risks
Common: nausea, vomiting, diarrhea, constipation, abdominal pain. These typically decrease over time. May cause injection site reactions.
Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2 syndrome. Risk of pancreatitis, gallbladder disease, and potential retinopathy progression in diabetics.
Who Uses Semaglutide
Those seeking significant weight loss, Type 2 diabetics, individuals with obesity-related health conditions.
Frequently Asked Questions
Similar Peptides
View All Alternatives →Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.